CD274 and neoplasm: For example, durvalumab has been approved by the MHRA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer if at least 1% of their tumour cells express PD-L1 and their disease did not advance after previous platinum-based chemoradiotherapy19 (online supplemental table 1).